Article Contents ::
- 1 The Brand Name BACTOSPAR Has Generic Salt :: Sparfloxacin
- 2 BACTOSPAR Is From Company Graf Lab. Priced :: Rs. N.I.
- 3 BACTOSPAR have Sparfloxacin is comes under Sub class Quinolones of Main Class Anti Infectives
- 4 Main Medicine Class:: Anti Infectives Sub Medicine Class :: Quinolones
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name BACTOSPAR Has Generic Salt :: Sparfloxacin
BACTOSPAR Is From Company Graf Lab. Priced :: Rs. N.I.
BACTOSPAR have Sparfloxacin is comes under Sub class Quinolones of Main Class Anti Infectives
Main Medicine Class:: Anti Infectives Sub Medicine Class :: Quinolones
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Sparfloxacin | TAB | Rs. N.I. | N.I |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / N.I |
| BACTOSPAR | Graf Lab. | 200MG | N.I | Rs. N.I. |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Graf Lab. :: BACTOSPAR | Sparfloxacin | Anti Infectives | Quinolones |
Indications for Drugs ::
Chronic bronchitis, Community-acquired pneumonia
Drug Dose ::
Adult: PO Acute bacterial exacerbation of chronic bronchitis; Community-acquired pneumonia 100-300 mg/day in 1-2 divided doses.
Contraindication ::
Hypersensitivity; pregnancy and lactation; children <18 yr. Drug Precautions ::
History of CNS disorders, pseudomembranous colitis, superinfection, severe renal dysfunction, epilepsy, G6PD deficiency, myasthenia gravis, patients with QT prolongation, uncorrected electrolyte disturbances, bradycardia, or pre-existing cardiac disease. Avoid exposure to strong sunlight or sunlamps during treatment. Discontinue treatment if patients experience tendon pain, inflammation or rupture; subsequent use of fluoroquinolones in these patients is not recommended. Avoid in MRSA infections due to high risk of resistance. Ensure adequate fluid intake to reduce risk of crystalluria.
Drug Side Effects ::
Diarrhoea, abdominal pain, nausea, vomiting; jaundice, renal failure, elevation of liver enzymes, BUN and creatinine; anaphylactoid reaction, headache, dizziness, convulsions; tremors, myalgia; rhabdomyolysis, thrombocytopenia and eosinophilia. Potentially Fatal: AV block; anaphylaxis.
Pregnancy category ::
3
Drug Mode of Action ::
Sparfloxacin inhibits the supercoiling activity of DNA gyrase which is an enzyme essential for DNA replication thus promoting the breakage of DNA structures. It has activity against S. pneumoniae, S. aureus, H. influenzae, K. pneumoniae, M. catarrhalis and Mycobacterium spp.
Drug Interactions ::
Cations such as aluminum, magnesium, zinc and iron may reduce the bioavailability of sparfloxacin. May increase the plasma concentrations of theophylline and tizanidine. May enhance the effect of warfarin and glibenclamide. May decrease the renal clearance of methotrexate. Excretion may be reduced by probenecid. May alter serum levels of phenytoin. Potentially Fatal: Corticosteroids may increase risk of tendon rupture. Increased risk of seizures with NSAIDs. Risk of additive QT prolongation effect when used with class Ia or III antiarrhythmic drugs, astemizole, terfenadine, cisapride, erythromycin, pentamidine, phenothiazines or TCAs.
